Totaligent, Inc. entered into Definitive Agreement with Ivan Klarich (effective 2026-04-10).
“On April 10, 2026, Totaligent, Inc. (the “Company”) entered into a Definitive Agreement (the “Definitive Agreement”) with Ivan Klarich (“Klarich”).”
Source-grounded facts extracted from Totaligent, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Totaligent, Inc. entered into Definitive Agreement with Ivan Klarich (effective 2026-04-10).
“On April 10, 2026, Totaligent, Inc. (the “Company”) entered into a Definitive Agreement (the “Definitive Agreement”) with Ivan Klarich (“Klarich”).”
Totaligent, Inc. amended Extension Amendment with GloMed Solutions Limited Liability Company (effective 2026-03-22).
“On March 22, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 22, 2026 (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”).”
Totaligent, Inc. amended Extension Amendment with Aetherium Medical (effective 2026-03-04).
“On March 4, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 11, 2026 (the “LOI”) with Aetherium Medical (“Aetherium”).”
Totaligent, Inc. amended Extension Amendment with Aetherium Medical (effective 2026-03-04).
“On March 4, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 11, 2026 (the “LOI”) with Aetherium Medical (“Aetherium”).”
Totaligent, Inc. entered into Binding Letter of Intent with GloMed Solutions Limited Liability Company (effective 2026-02-22).
“On February 22, 2026, Totaligent, Inc. (the “Company”) entered into a Binding Letter of Intent (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”).”
Totaligent, Inc. entered into Binding Letter of Intent with Aetherium Medical (effective 2026-02-11).
“On February 11, 2026, Totaligent, Inc. (the “Company”) entered into a Binding Letter of Intent (the “LOI”) with Aetherium Medical (“Aetherium”).”
Ben Hansel resigned as director at Totaligent, Inc..
“Effective April 18, 2025, Ben Hansel resigned as a director of Totaligent, Inc. (the “Company”).”
Brian Heckathorne was elected as director at Totaligent, Inc..
“Effective April 18, 2025, the Board of Directors of the Company elected Brian Heckathorne to serve as a director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.